Publications
Members of the Metabolic Continuum Roundtable™ contribute important research to the public domain through peer-reviewed articles in medical journals. Below is a selection of recent research co-authored by Roundtable contributors. For a comprehensive search of metabolic-related research by Roundtable contributors and others, visit pubmed.gov.
Filter
February 2025
EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis.
View PublicationFebruary 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors’ Perspective.
View PublicationFebruary 2025
Non-invasive evaluation of steatosis and fibrosis in the liver in adult patients living with cystic fibrosis.
View PublicationFebruary 2025
A European Survey to Identify Challenges in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease.
View PublicationFebruary 2025
Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD.
View PublicationJanuary 2025
Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis.
View PublicationJanuary 2025
Effect of Target-Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function.
View PublicationJanuary 2025
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease.
View PublicationJanuary 2025
Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes.
View PublicationJanuary 2025
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease.
View PublicationNovember 2024
Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis.
View PublicationNovember 2024
Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH).
View PublicationNovember 2024
Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021.
View PublicationJuly 2024
Swept up in the tsunami: Pediatric and adolescent steatotic (fatty) liver disease.
View PublicationJuly 2024
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials.
View PublicationJune 2024
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).
View PublicationJune 2024
The fibroblast hormone endotrophin is a biomarker of mortality in chronic diseases.
View PublicationJune 2024
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
View PublicationJune 2024
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
View PublicationJune 2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
View PublicationJune 2024
Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis – prevalence, clinical impact, economic implications and management strategies.
View PublicationJune 2024
Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity.
View PublicationJune 2024
Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.
View PublicationJune 2024
The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
View PublicationJune 2024
Changing from NAFLD to MASLD: The implications for health-related quality of life data.
View PublicationMay 2024
Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept study.
View PublicationMay 2024
The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD).
View PublicationMay 2024
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.
View PublicationMay 2024
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
View PublicationMay 2024
Increases and decreases in liver stiffness measurements are independently associated with the risk of liver-related events in NAFLD.
View PublicationMay 2024
Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis.
View PublicationMay 2024
High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.
View PublicationMay 2024
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis.
View PublicationMay 2024
Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome.
View PublicationMay 2024
Health-related quality of life in non-alcoholic fatty liver disease: A cross-cultural study between Spain and the United Kingdom.
View PublicationMay 2024
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
View PublicationApril 2024
BCG Vaccination-Associated Lower HbA1c and Increased CD25 Expression on CD8+ T Cells in Patients with Type 1 Diabetes in Ghana.
View PublicationApril 2024
Cost-effectiveness of diagnosis and treatment of early gestational diabetes mellitus: economic evaluation of the TOBOGM study, an international multicenter randomized controlled trial.
View PublicationApril 2024
PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.
View PublicationApril 2024
Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: A qualitative exploration of challenges and barriers.
View PublicationApril 2024
The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease.
View PublicationApril 2024
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
View PublicationApril 2024
Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis.
View PublicationApril 2024
Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction.
View PublicationApril 2024
Metabolic dysfunction-associated steatohepatitis (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) require urgent attention by primary care physicians and endocrinologists.
View PublicationApril 2024
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.
View PublicationApril 2024
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
View PublicationApril 2024
Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
View PublicationDecember 2023
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial.
View PublicationDecember 2023
Nutrition assessment and MASH severity in children using the Healthy Eating Index.
View PublicationDecember 2023
Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplantations in the U.S.: Data From a National Registry.
View PublicationNovember 2023
Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease.
View PublicationNovember 2023
A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis.
View PublicationNovember 2023
A nutrigenetic precision approach for the management of non-alcoholic fatty liver disease.
View PublicationNovember 2023
Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS).
View PublicationNovember 2023
Looking for the best algorithm in diabetes population for advanced fibrosis detection: The best is the enemy of the good.
View PublicationNovember 2023
Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease.
View PublicationNovember 2023
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
View PublicationOctober 2023
Risk factors for fibrosis progression in non-alcoholic steatohepatitis: analysis of the European cohort in the real-world GAIN study.
View PublicationOctober 2023
Homeostasis Model Assessment of β-Cell Function for Diagnosis of Insulinoma.
View PublicationOctober 2023
Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score.
View PublicationOctober 2023
Impact of physical fitness and exercise training on subcutaneous adipose tissue beiging markers in humans with and without diabetes and a high-fat diet-fed mouse model.
View PublicationOctober 2023
Precise glucose measurement in sodium fluoride-citrate plasma affects estimates of prevalence in diabetes and prediabetes.
View PublicationOctober 2023
Reduced Insulin Clearance Differently Relates to Increased Liver Lipid Content and Worse Glycemic Control in Recent-Onset Type 2 and Type 1 Diabetes.
View PublicationOctober 2023
A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis.
View PublicationOctober 2023
Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions.
View PublicationOctober 2023
Long-term follow-up of web-based and group-based behavioural intervention in NAFLD in a real world clinical setting.
View PublicationOctober 2023
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus.
View PublicationOctober 2023
Nutrition could prevent or promote non-alcoholic fatty liver disease: an opportunity for intervention.
View PublicationOctober 2023
Correlates of Skeletal Muscle Mass and Differences Between Novel Subtypes in Recent-onset Diabetes.
View PublicationOctober 2023
Risk of severe infection in patients with non-alcoholic fatty liver disease: Implication on clinical management.
View PublicationOctober 2023
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions.
View PublicationSeptember 2023
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.
View PublicationSeptember 2023
A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis.
View PublicationSeptember 2023
Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplantations in the U.S.: Data From a National Registry.
View PublicationSeptember 2023
MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease.
View PublicationSeptember 2023
Brain insulin action on peripheral insulin sensitivity in women depends on menstrual cycle phase.
View PublicationSeptember 2023
Association of thyroid function with non-alcoholic fatty liver disease in recent-onset diabetes.
View PublicationSeptember 2023
Accuracy, reliability and comprehensiveness of ChatGPT generated medical responses for patients with NAFLD.
View PublicationSeptember 2023
Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD).
View PublicationSeptember 2023
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis.
View PublicationSeptember 2023
The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis.
View PublicationSeptember 2023
Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes.
View PublicationSeptember 2023
NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study.
View PublicationSeptember 2023
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
View PublicationSeptember 2023
Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease.
View PublicationAugust 2023
Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
View PublicationAugust 2023
Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.
View PublicationAugust 2023
Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register.
View PublicationAugust 2023
AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
View PublicationAugust 2023
Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.
View PublicationAugust 2023
Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease.
View PublicationAugust 2023
Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD – An Umbrella Overview of Systematic Review of Meta-Analysis.
View PublicationAugust 2023
Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases.
View PublicationAugust 2023
At the dawn of potent therapeutics for fatty liver disease – introducing the miniseries on promising pharmacological targets for NASH.
View PublicationJuly 2023
The effects of extracellular vesicles and their cargo on metabolism and its adaptation to physical exercise in insulin resistance and type 2 diabetes.
View PublicationJuly 2023
Serum identification of At-Risk MASH: The Metabolomics-Advanced steatohepatitis fibrosis score (MASEF).
View PublicationJuly 2023
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis.
View PublicationJuly 2023
Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes Mellitus.
View PublicationJuly 2023
Impact of Chronotype and Mediterranean Diet on the Risk of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.
View PublicationJuly 2023
Nonalcoholic fatty liver disease mortality may not be decreasing: A need for careful interpretation of GBD 2019 estimates of liver deaths.
View PublicationJuly 2023
Post-Transplant Diabetes Mellitus: Recent Developments in Pharmacological Management of Hyperglycemia.
View PublicationJuly 2023
Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD.
View PublicationJuly 2023
How to Identify Advanced Nonalcoholic Fatty Liver Disease in the Primary Care Setting.
View PublicationJune 2023
Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.
View PublicationJune 2023
Erratum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.
View PublicationJune 2023
Natural history of NASH cirrhosis in liver transplant waitlist registrants.
View PublicationJune 2023
How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials.
View PublicationJune 2023
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
View PublicationJune 2023
Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial.
View PublicationJune 2023
Evaluation of 2-year outcomes in infants born to mothers with and without NAFLD in pregnancy.
View PublicationJune 2023
Dynamic Glucose-Enhanced Imaging of the Liver Using Breath-Hold Black Blood Quantitative T1ρ MRI at 3.0 T.
View PublicationJune 2023
MIC26 and MIC27 are bona fide subunits of the MICOS complex in mitochondria and do not exist as glycosylated apolipoproteins.
View PublicationJune 2023
Agile3+ and Agile4: two diagnostic scores that synergize for the prognostic assessment in NAFLD.
View PublicationJune 2023
Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbidities.
View PublicationJune 2023
A Phase 2a active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease.
View PublicationJune 2023
Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD.
View PublicationJune 2023
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.
View PublicationJune 2023
Trajectories of glycaemic traits exhibit sex-specific associations with hepatic iron and fat content: Results from the KORA-MRI study.
View PublicationJune 2023
A Phase 2a active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease.
View PublicationMay 2023
Economic Burden and Patient-Reported Outcomes of Nonalcoholic Fatty Liver Disease.
View PublicationMay 2023
Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Cardiovascular Diseases.
View PublicationMay 2023
Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease.
View PublicationMay 2023
Nonalcoholic Fatty Liver Disease: A Unique Entity or Part of the Metabolic Syndrome or Both.
View PublicationMay 2023
Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease.
View PublicationMay 2023
Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease.
View PublicationApril 2023
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.
View PublicationApril 2023
Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study.
View PublicationApril 2023
Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).
View PublicationApril 2023
Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study.
View PublicationApril 2023
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
View PublicationApril 2023
Validation of the blood test MACK-3 for the noninvasive diagnosis of fibrotic NASH: an international study with 1,924 patients.
View PublicationApril 2023
A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures.
View PublicationApril 2023
Study protocol for a randomized, controlled trial using a novel, family-centered diet treatment to prevent NAFLD in Hispanic children.
View PublicationApril 2023
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
View PublicationApril 2023
NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned.
View PublicationApril 2023
Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence.
View PublicationMarch 2023
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
View PublicationMarch 2023
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.
View PublicationMarch 2023
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
View PublicationMarch 2023
Review article: The need for more efficient and patient-oriented drug development pathways in NASH-setting the scene for platform trials.
View PublicationMarch 2023
Corrigendum to: “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort<sup>☆</sup>” [J Hepatol (2020) 505-515].
View PublicationMarch 2023
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
View PublicationMarch 2023
Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.
View PublicationMarch 2023
Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints.
View PublicationMarch 2023
Validation of a Clinical Risk-Based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.
View PublicationMarch 2023
Using Real-World Electronic Health Record Data to Assess Chronic Disease Screening in Children: A Case Study of Non-Alcoholic Fatty Liver Disease.
View PublicationMarch 2023
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
View PublicationMarch 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.
View PublicationMarch 2023
Machine learning algorithm improves detection of NASH (NAS-based) and at-risk NASH, a development and validation study.
View PublicationMarch 2023
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes.
View PublicationMarch 2023
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
View PublicationMarch 2023
Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease.
View PublicationFebruary 2023
Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients.
View PublicationFebruary 2023
Lower Hepatic Fat Is Associated With Improved Insulin Secretion in a High-Risk Prediabetes Subphenotype During Lifestyle Intervention.
View PublicationFebruary 2023
Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
View PublicationFebruary 2023
Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study.
View PublicationFebruary 2023
Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based Programs.
View PublicationFebruary 2023
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.
View PublicationFebruary 2023
Recent Research and Insights on the Disease Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
View PublicationFebruary 2023
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
View PublicationFebruary 2023
Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties.
View PublicationFebruary 2023
Sarcopenia Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD) is Associated with Advanced Fibrosis.
View PublicationFebruary 2023
A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis.
View PublicationJanuary 2023
Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease.
View PublicationJanuary 2023
Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.
View PublicationJanuary 2023
Nonalcoholic Fatty Liver Disease Is Independently Associated With Higher All-Cause and Cause-Specific Mortality.
View PublicationJanuary 2023
Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study.
View PublicationJanuary 2023
The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease.
View PublicationJanuary 2023
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
View PublicationJanuary 2023
Rational combination therapy for NASH: Insights from clinical trials and error.
View PublicationDecember 2022
Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD.
View PublicationDecember 2022
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH.
View PublicationDecember 2022
A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia
View PublicationDecember 2022
Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)
View PublicationNovember 2022
MAFLD vs. NAFLD not an emotional political process – rather Evidence-Based Medicine
View PublicationNovember 2022
Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients with Type 2 Diabetes and NAFLD
View PublicationNovember 2022
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
View PublicationNovember 2022
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
View PublicationNovember 2022
Restoration of CD4+ T Cells during NAFLD without Modulation of the Hepatic Immunological Pattern Is Not Sufficient to Prevent HCC
View PublicationNovember 2022
Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis
View PublicationNovember 2022
Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes
View PublicationNovember 2022
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
View PublicationNovember 2022
Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective
View PublicationNovember 2022
Vitality, mental health and role-physical mediate the influence of coping on depressive symptoms and self-efficacy in patients with non-alcoholic fatty liver disease: A cross-sectional study
View PublicationOctober 2022
Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies
View PublicationOctober 2022
A Meta-Analysis on Associated Risk of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD)
View PublicationOctober 2022
Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
View PublicationOctober 2022
Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-DM2 study
View PublicationOctober 2022
RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression
View PublicationOctober 2022
Impaired Myocardial Mitochondrial Respiration in Humans With Prediabetes: A Footprint of Prediabetic Cardiomyopathy
View PublicationOctober 2022
Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons
View PublicationOctober 2022
The Spectrum and Impact of Metabolic Dysfunction in MAFLD. A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals
View PublicationOctober 2022
Relative validity of a glycemic index extended food-frequency questionnaire
View PublicationOctober 2022
Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient data
View PublicationSeptember 2022
Hyperbaric oxygen rapidly improves tissue-specific insulin sensitivity and mitochondrial capacity in humans with type 2 diabetes: a randomised placebo-controlled crossover trial
View PublicationSeptember 2022
Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus Non-alcoholic fatty liver disease: A longitudinal cohort analysis
View PublicationSeptember 2022
A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD)
View PublicationSeptember 2022
Metabolic Factors Predict Changes in Endothelial Function During the Early Course of Type 1 and Type 2 Diabetes
View PublicationSeptember 2022
NAFLD and thyroid function: pathophysiological and therapeutic considerations
View PublicationSeptember 2022
The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: Data from National Health and nutrition examination survey 2005-2010 and 2017-2018
View PublicationSeptember 2022
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
View PublicationSeptember 2022
The Cost of Diagnosing and Managing Non-alcoholic Steatohepatitis in Europe and the United States
View PublicationSeptember 2022
Geographical similarity and differences in the burden and genetic predisposition of NAFLD
View PublicationSeptember 2022
Interactive Role of Surrogate Liver Fibrosis Assessment and Insulin Resistance on the Incidence of Major Cardiovascular Events
View PublicationSeptember 2022
Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine
View PublicationSeptember 2022
Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world
View PublicationAugust 2022
Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease
View PublicationAugust 2022
Metabolic factors predict changes in endothelial function during the early course of type 1 and type 2 diabetes
View PublicationAugust 2022
Historical Changes in Weight Classes and the Influence of NAFLD Prevalence: A Population Analysis of 34,486 Individuals
View PublicationAugust 2022
Developing and pilot testing an oral health screening tool for diabetes care providers
View PublicationAugust 2022
Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality
View PublicationJuly 2022
The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database
View PublicationJuly 2022
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals
View PublicationJuly 2022
Treatments for obesity in the context of nonalcoholic steatohepatitis and mental health
View PublicationJuly 2022
Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients
View PublicationJuly 2022
Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey
View PublicationJuly 2022
Liver stiffness accuracy by MR elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort
View PublicationJuly 2022
Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease
View PublicationJuly 2022
The scaffold-dependent function of RIPK1 in experimental non-alcoholic steatohepatitis
View PublicationJuly 2022
Fatty liver indices and their association with glucose metabolism in pregnancy – An observational cohort study.
View PublicationJuly 2022
A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin Dimer
View PublicationJune 2022
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH
View PublicationJune 2022
Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores
View PublicationJune 2022
A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation
View PublicationJune 2022
African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population
View PublicationJune 2022
Incidence of Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease
View PublicationJune 2022
Artificial Intelligence Improves Pathologist Agreement for Fibrosis Scores in Nonalcoholic Steatohepatitis Patients
View PublicationJune 2022
Comorbidities in Recent-Onset Adult Type 1 Diabetes: A Comparison of German Cohorts
View PublicationMay 2022
Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool
View PublicationMay 2022
The Effect of Diabetes and Prediabetes on the Prevalence, Complications and Mortality in Non-alcoholic Fatty Liver Disease
View PublicationMay 2022
Prevalence estimation of significant fibrosis due to NASH in Spain combining transient elastography and histology
View PublicationMay 2022
Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study
View PublicationMay 2022
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD
View PublicationMay 2022
Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018
View PublicationMay 2022
Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease
View PublicationMay 2022
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)
View PublicationMay 2022
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)
View PublicationMay 2022
Response to: “Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?”
View PublicationMay 2022
Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
View PublicationApril 2022
A global view of the interplay between non-alcoholic fatty liver disease and diabetes.
View PublicationApril 2022
Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes.
View PublicationApril 2022
A nutrigenetic tool for precision dietary management of NAFLD deeming insulin resistance markers
View PublicationApril 2022
Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science
View PublicationApril 2022
Greater ectopic fat deposition and liver fibroinflammation, and lower skeletal muscle mass in people with type 2 diabetes
View PublicationMarch 2022
Risk of liver-related events by age and diabetes duration in diabetic patients with non-alcoholic fatty liver disease.
View PublicationMarch 2022
Non-Alcoholic fatty liver disease-associated DNA methylation and gene expression alterations in the livers of Collaborative Cross mice fed an obesogenic high-fat and high-sucrose diet.
View PublicationMarch 2022
A Simple Test to Identify the Risk of NASH and Cirrhosis in People with Obesity or Diabetes: The Time to Screen is Now.
View PublicationMarch 2022
Reliability of Histologic Assessment for NAFLD and Development of an Expanded NAFLD Activity Score.
View PublicationMarch 2022
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
View PublicationMarch 2022
Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.
View PublicationMarch 2022
Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis.
View PublicationMarch 2022
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.
View PublicationMarch 2022
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).
View PublicationMarch 2022
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.
View PublicationMarch 2022
Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease.
View PublicationMarch 2022
NAFLD increases Risk of Carotid Atherosclerosis and Ischemic Stroke. An Updated Meta-Analysis with 135,602 Individuals.
View PublicationMarch 2022
A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease.
View PublicationMarch 2022
Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation.
View PublicationMarch 2022
Association of Obesity, Diabetes, and Alcohol Use With Liver Fibrosis Among US Adults With Hepatitis C Virus Infection.
View PublicationMarch 2022
Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project.
View PublicationMarch 2022
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease
View PublicationMarch 2022
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk
View PublicationFebruary 2022
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.
View PublicationFebruary 2022
Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients.
View PublicationFebruary 2022
Differential fuel utilization in liver transplant recipients and its relationship with non-alcoholic fatty liver disease.
View PublicationFebruary 2022
Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium.
View PublicationFebruary 2022
Dual roles of B lymphocytes in mouse models of diet-induced nonalcoholic fatty liver disease.
View PublicationFebruary 2022
Meaning of non-overlapping patients between the MAFLD and NAFLD definitions.
View PublicationFebruary 2022
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
View PublicationJanuary 2022
Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.
View PublicationJanuary 2022
Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation.
View PublicationJanuary 2022
Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.
View PublicationJanuary 2022
Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.
View PublicationJanuary 2022
Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis.
View PublicationJanuary 2022
Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
View PublicationJanuary 2022
Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.
View PublicationJanuary 2022
Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.
View PublicationDecember 2021
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
View PublicationDecember 2021
Elevated liver enzymes and comorbidities in type 2 diabetes: Multicenter analysis of 51,645 patients of the DPV database.
View PublicationDecember 2021
An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD.
View PublicationDecember 2021
Evaluation of a Stepped Care Approach to Manage Depression and Diabetes Distress in Patients with Type 1 Diabetes and Type 2 Diabetes: Results of a Randomized Controlled Trial (ECCE HOMO Study).
View PublicationDecember 2021
The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.
View PublicationDecember 2021
Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready-to-use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males.
View PublicationDecember 2021
Corrigendum to ‘Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis’ [J Hepatol 75 (2021) 865-878].
View PublicationDecember 2021
Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis.
View PublicationDecember 2021
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach.
View PublicationDecember 2021
A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy.
View PublicationDecember 2021
Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
View PublicationDecember 2021
Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population.
View PublicationDecember 2021
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.
View PublicationNovember 2021
Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.
View PublicationNovember 2021
Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.
View PublicationNovember 2021
Outcomes of Non-alcoholic Steatohepatitis following Liver Transplantation. An Updated Meta-analysis and Systematic Review.
View PublicationNovember 2021
Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes.
View PublicationNovember 2021
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
View PublicationNovember 2021
Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C.
View PublicationNovember 2021
The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review.
View PublicationNovember 2021
Comparison of patient characteristics between East Asian and non-East Asian patients with insulin autoimmune syndrome.
View PublicationNovember 2021
Physical fitness and cardiovascular risk factors in the novel diabetes subgroups.
View PublicationNovember 2021
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global NASH/NAFLD Registry.
View PublicationNovember 2021
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
View PublicationNovember 2021
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
View PublicationNovember 2021
Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.
View PublicationNovember 2021
The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma.
View PublicationNovember 2021
The peroxisomal transporter ABCD3 plays a major role in hepatic dicarboxylic fatty acid metabolism and lipid homeostasis.
View PublicationNovember 2021
Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis.
View PublicationOctober 2021
Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies.
View PublicationOctober 2021
Dietary palmitate and oleate differently modulate insulin sensitivity in human skeletal muscle.
View PublicationOctober 2021
Advancing the global public health agenda for NAFLD: a consensus statement.
View PublicationOctober 2021
Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis.
View PublicationOctober 2021
Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus Coinfection.
View PublicationOctober 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
View PublicationOctober 2021
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
View PublicationOctober 2021
Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.
View PublicationOctober 2021
Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong.
View PublicationOctober 2021
The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States.
View PublicationOctober 2021
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial.
View PublicationOctober 2021
Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.
View PublicationOctober 2021
Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.
View PublicationOctober 2021
Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitis.
View PublicationSeptember 2021
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.
View PublicationSeptember 2021
A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Non-alcoholic Fatty Liver Disease.
View PublicationSeptember 2021
Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review.
View PublicationSeptember 2021
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
View PublicationSeptember 2021
Cross-Talk Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: Implications for Future Trial Design.
View PublicationSeptember 2021
Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies.
View PublicationSeptember 2021
Fatty Pancreas Is Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study.
View PublicationAugust 2021
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
View PublicationJuly 2021
Hepatic Fat Reduction Due to Resmetirom in Patients with Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.
View PublicationJuly 2021
Novel Antidiabetic Strategies and Diabetologists’ Views in Nonalcoholic Steatohepatitis.
View PublicationJuly 2021
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.
View PublicationJuly 2021
Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis.
View PublicationJuly 2021
PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.
View PublicationJuly 2021
A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease.
View PublicationJune 2021
Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes.
View PublicationJune 2021
Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis.
View PublicationJune 2021
Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease.
View PublicationJune 2021
Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.
View PublicationJune 2021
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
View PublicationJune 2021
Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need.
View PublicationJune 2021
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.
View PublicationJune 2021
Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.
View PublicationJune 2021
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
View PublicationMay 2021
Influence of Psychological Biomarkers on Therapeutic Adherence by Patients with Non-Alcoholic Fatty Liver Disease: A Moderated Mediation Model.
View PublicationMay 2021
The Burden of Nonalcoholic Fatty Liver Disease in Asia, Middle East and North Africa: Data from Global Burden of Disease 2009-2019.
View PublicationMay 2021
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
View PublicationMay 2021
Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
View PublicationMay 2021
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis.
View PublicationMay 2021
Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis.
View PublicationMay 2021
Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers.
View PublicationFebruary 2021
Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study.
View PublicationFebruary 2021
Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.
View PublicationFebruary 2021
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.
View PublicationFebruary 2021
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in five european countries in 2018: A cost-of-illness analysis.
View PublicationFebruary 2021
Simple non-invasive scoring systems and histologic scores in predicting mortality in NAFLD patients: A systematic review and meta-analysis.
View PublicationFebruary 2021
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
View PublicationFebruary 2021
Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: A population -based study.
View PublicationJanuary 2021
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.
View PublicationJanuary 2021
Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement.
View PublicationJanuary 2021
Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD).
View PublicationJanuary 2021
Relevance of fructose intake in adolescence for fatty liver indices in young adulthood.
View PublicationJanuary 2021
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
View PublicationDecember 2020
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis.
View PublicationDecember 2020
Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart.
View PublicationDecember 2020
Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis.
View PublicationDecember 2020
Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans.
View PublicationDecember 2020
“The predictive value of significant fibrosis for metabolic disturbances in NAFLD patients”.
View PublicationDecember 2020
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
View PublicationDecember 2020
Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension.
View PublicationDecember 2020
Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes.
View PublicationDecember 2020
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
View PublicationDecember 2020
Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease.
View PublicationDecember 2020
Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study.
View PublicationDecember 2020
Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.
View PublicationDecember 2020
Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.
View PublicationDecember 2020
AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review.
View PublicationDecember 2020
Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.
View PublicationDecember 2020
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early phase randomized trials.
View PublicationDecember 2020
The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH).
View PublicationDecember 2020
Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?
View PublicationNovember 2020
Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease.
View PublicationNovember 2020
A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients.
View PublicationNovember 2020
Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus.
View PublicationNovember 2020
Overall clinical and economic impact of non-alcoholic fatty liver disease.
View PublicationNovember 2020
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
View PublicationNovember 2020
Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P.
View PublicationNovember 2020
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
View PublicationNovember 2020
Non-alcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.
View PublicationNovember 2020
Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice.
View PublicationNovember 2020
Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH.
View PublicationNovember 2020
Clinical utility of change in nonalcoholic fatty liver disease activity score and change in fibrosis in NAFLD.
View PublicationNovember 2020
A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients with Nonalcoholic Steatohepatitis.
View PublicationOctober 2020
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.
View PublicationOctober 2020
3D analysis of microvasculature in murine liver fibrosis models using synchrotron radiation-based microtomography.
View PublicationOctober 2020
Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.
View PublicationOctober 2020
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.
View PublicationOctober 2020
In vivo absolute quantification of hepatic γ-ATP concentration in mice using 31 P MRS at 11.7 T.
View PublicationOctober 2020
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.
View PublicationOctober 2020
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
View PublicationSeptember 2020
ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis.
View PublicationSeptember 2020
Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease.
View PublicationSeptember 2020
Dietary Rapeseed Oil Supplementation Reduces Hepatic Steatosis in Obese Men – A Randomized Controlled Trial.
View PublicationSeptember 2020
Clinical endpoints are necessary in the interim analysis of REGENERATE – Authors’ reply.
View PublicationSeptember 2020
A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease.
View PublicationSeptember 2020
CPAP Did Not Improve Nonalcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea: A Randomized Clinical Trial.
View PublicationSeptember 2020
Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts.
View PublicationAugust 2020
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.
View PublicationJuly 2020
Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.
View PublicationJuly 2020
Physical Activity, Measured Objectively, is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease.
View PublicationJuly 2020
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
View PublicationJuly 2020
The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology.
View PublicationJuly 2020
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
View PublicationJuly 2020
Review article: The impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
View PublicationJuly 2020
Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
View PublicationJuly 2020
Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease.
View PublicationJuly 2020
Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus.
View PublicationJune 2020
What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist’s Perspective.
View PublicationJune 2020
Mitochondrial oxidative injury: A key player in nonalcoholic fatty liver disease.
View PublicationJune 2020
Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients.
View PublicationJune 2020
Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong.
View PublicationMay 2020
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
View PublicationApril 2020
Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model.
View PublicationApril 2020
Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population.
View PublicationApril 2020
Longitudinal relationship of amino acids and indole metabolites with long-term body mass index and cardiometabolic risk markers in young individuals.
View PublicationApril 2020
Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.
View PublicationApril 2020
A new definition for metabolic associated fatty liver disease: an international expert consensus statement.
View PublicationApril 2020
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.
View PublicationApril 2020
Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis.
View PublicationApril 2020
Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed.
View PublicationApril 2020
Increased Release of Proinflammatory Proteins in Primary Human Adipocytes and Activation of the Inflammatory NFĸB, p38, and ERK Pathways upon Omentin Treatment.
View PublicationApril 2020
Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis.
View PublicationApril 2020
Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease.
View PublicationApril 2020
Outcomes of liver transplantation by insurance types in the United States.
View PublicationMarch 2020
Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy.
View PublicationMarch 2020
Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges.
View PublicationMarch 2020
Lysyl oxidase (LOX) family members: rationale and their potential as therapeutic targets for liver fibrosis.
View PublicationFebruary 2020
Longitudinal Association of Non-Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study.
View PublicationFebruary 2020
Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly.
View PublicationFebruary 2020
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease.
View PublicationFebruary 2020
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of Nonalcoholic Fatty Liver Disease.
View PublicationFebruary 2020
MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease.
View PublicationFebruary 2020
Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis.
View PublicationFebruary 2020
Investigating fibrosis and inflammation in an ex vivo NASH murine model.
View PublicationFebruary 2020
Non-Alcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
View PublicationFebruary 2020
The role of nutrition in non-alcoholic fatty liver disease: Pathophysiology and management.
View PublicationFebruary 2020
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes.
View PublicationFebruary 2020
Role of Exercise in Mitigating Pediatric Nonalcoholic Fatty Liver Disease.
View PublicationFebruary 2020
A diabetologist’s perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions.
View PublicationJanuary 2020
Fatty liver disease: putting the spotlight on a silent menace for young adults.
View PublicationJanuary 2020
Multicenter validation of association between decline in MRI-PDFF and histologic response in nonalcoholic steatohepatitis.
View PublicationJanuary 2020
Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
View PublicationDecember 2019
Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study.
View PublicationDecember 2019
Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.
View PublicationNovember 2019
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
View PublicationNovember 2019
The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease.
View PublicationNovember 2019
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
View PublicationNovember 2019
Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
View PublicationNovember 2019
Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease.
View PublicationNovember 2019
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
View PublicationNovember 2019
Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes.
View PublicationNovember 2019
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
View PublicationOctober 2019
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
View PublicationOctober 2019
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
View PublicationSeptember 2019
Editorial: It is not a wide-open field for incretins – collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis
View PublicationAugust 2019
Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis
View PublicationAugust 2019
Non-alcoholic fatty liver disease in Asia: How is it different from the West?
View PublicationAugust 2019
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
View PublicationJuly 2019
FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice
View PublicationJuly 2019
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
View PublicationJuly 2019
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
View PublicationJuly 2019
Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes
View PublicationJuly 2019
Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease
View PublicationJuly 2019
Neurocognitive Deficits in a Cohort With Class 2 and Class 3 Obesity: Contributions of Type 2 Diabetes and Other Comorbidities
View PublicationJune 2019
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
View PublicationJune 2019
Development and Validation of Hepamet Fibrosis Scoring System A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
View PublicationJune 2019
Past, present and future perspectives in nonalcoholic fatty liver disease.
View PublicationJune 2019
Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.
View PublicationJune 2019
Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
View PublicationJune 2019
Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma.
View PublicationMay 2019
Are Non-alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease More Than Just Semantics?
View PublicationMay 2019
Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis.
View PublicationMay 2019
Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.
View PublicationApril 2019
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum.
View PublicationApril 2019
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
View PublicationApril 2019
Metabolic characterization of two different non-alcoholic fatty liver disease pre-clinical mouse models.
View PublicationApril 2019
Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria.
View PublicationApril 2019
Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD).
View PublicationMarch 2019
Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.
View PublicationMarch 2019
Plasma Fibroblast Growth Factor 21 is Associated with Severity of Nonalcoholic Steatohepatitis in Patients with Obesity and Type 2 Diabetes.
View PublicationMarch 2019
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis.
View PublicationMarch 2019
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
View PublicationFebruary 2019
Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis.
View PublicationJanuary 2019
Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis.
View PublicationJanuary 2019
Diagnostic Accuracy of Non-Invasive Fibrosis Models to Detect Change in Fibrosis Stage.
View PublicationDecember 2018